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Abstract
Background: As more patients with cystic fibrosis (CF) reach adulthood and participate in age-appropriate
activities (e.g. employment, dating), disclosure of medical status becomes more important. This study assessed rates
of disclosure and its perceived impact on relationships using the Adult Data for Understanding Lifestyle and
Transitions (ADULT) online survey.
Methods: Adults with CF participated in the survey via the United States national network of CF Centers.
Descriptive and inferential statistics were utilized.
Results: Participants (n = 865) were more likely to disclose to relatives (94%) and close friends (81%) than to
dating partners (73%), bosses/supervisors/teachers (51%) or co-workers (39%). Respondents generally reported a
neutral/positive effect on relationships following disclosure. Negative effects of disclosure were infrequent, but
more likely with dating partners or bosses/supervisors/teachers. Results also indicated that disclosure may be
influenced by severity of lung disease and gender, with those having normal/mild lung disease less likely to
disclose their diagnosis to both co-workers (p < 0.01) and bosses/supervisors/teachers (p < 0.01), and women
being more likely to disclose to close friends (p < 0.0001) and dating partners (p < 0.05) than men.
Conclusions: Most adults with CF disclosed their disease to relatives and close friends. Individuals with severe CF
lung disease were more likely to disclose their diagnosis to coworkers and supervisors/teachers. It may be helpful
to provide support for disclosure of disease in situations such as employment and dating.
Background
Due to the early onset and progressive nature of cystic
fibrosis (CF), as well as the relatively short life expec-
tancy, CF was previously considered a childhood disor-
der. However, earlier diagnosis and the development of
new treatments over the past two decades have consider-
ably improved the survival of patients with CF. Results
from the United States (US) CF Foundation 2008 Patient
Registry report indicated that median life expectancy of
patients with CF has risen from approximately 25 years
in 1985 to over 37 years in 2008[1]. Furthermore, the
percentage of patients with CF aged 18 years or older has
risen from 30% in 1990 to over 46% in 2008, leading to a
greater emphasis on the acquisition of adult roles[1].
Coupled with an improved life expectancy, patients
w i t hC Fa r em o r el i k e l yt os e e ki n d e p e n d e n c ef r o mt h e i r
families and pursue typical adult activities (e.g. attending
college, entering serious relationships and pursuing
careers)[2]. During adolescence, individuals want to feel
‘normal’ and reduce the sense that they are different
from their peers. This may lead them to keep disease sta-
tus a ‘secret’ or hide visible aspects of the disease (e.g.
suppressing cough)[3]. However, in their transition to
adulthood, different social contexts and relationships
may require disclosure of their CF[4]. For example, con-
cerns about employer-based health insurance may need
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vement in romantic relationships requires disclosure for
long-term planning, including marriage and children.
While the area of disclosure has been a focus of research
in several other diseases including HIV/AIDS, epilepsy
and mental health[5-9], little research has been con-
ducted on disclosure in CF, particularly during emerging
adulthood [4,10].
In order to better understand these issues, the Adult
Data for Understanding Lifestyle and Transitions
(ADULT) survey was conducted. The purpose of the
current study was to examine how adults with CF per-
ceive the disclosure process within specific personal and
professional relationships, and to better understand the
relationship of disease severity and gender to the disclo-
sure process.
Methods
Participants
Any adult aged ≥18 years with CF in the US could com-
plete this online survey. There were no additional inclu-
sion/exclusion criteria.
Procedures
From July 2007 to August 2007, adults with CF were
invited via the United States (US) national network of
CF Centers to participate in an anonymous, online sur-
vey. The survey consisted of five screening and 50 life-
style questions. Responses to medical (forced expiratory
volume in 1 second [FEV1], lung transplant and intrave-
nous [IV] treatment during the previous 12 months)
and screening questions were required for inclusion in
the dataset. The online survey was hosted by GfK Roper
(New York, NY, US) and $50 was given to each partici-
pant who qualified and completed the survey, with safe-
guards in place to prevent multiple responses per
patient. All authors sent the current protocol to their
respective Institutional Review Boards, with each IRB
deeming that approval was unnecessary due to the de-
identified nature of the anonymous survey. Consent to
participate was implicit to adult participants based on
completion of the survey.
Measure
Adult Data for Understanding Lifestyle and Transitions
(ADULT) survey
The survey consisted of 5 screening and 50 lifestyle ques-
tions, encompassing aspects of adult lifestyle and transi-
tions. Major survey categories included questions about
education, employment, activities, travel, financial, disabil-
ity, independent living, social relationships, children, gen-
eral health, disclosure to others, satisfaction with life,
medical information and history, and advice to others with
CF. For purpose of the current study, questions regarding
demographics (e.g., gender, age), medical information (e.g.
FEV1 % predicted, time since diagnosis), disclosure, and
challenges related to disclosure were utilized. The two
questions specific to disease disclosure were: a) “To what
extent do the following people know that you have CF:
Relatives, Close friends, Dating Partners, Neighbors,
Bosses/supervisors/teachers, Co-workers, and Acquain-
tances?” Response options were as follows: “None of
them”, “A few of them”, “Some of them”, “Most of them”,
“All of them”,o rN / A ;b )“After these people became
aware that you have CF, how did it affect your relation-
ship? Relatives, Close friends, Dating Partners, Neighbors,
Bosses/supervisors/teachers, Co-workers, and Acquain-
tances?” Response options were as follows: “Negative”,
“Mostly negative”, “No effect”, “Mostly positive”, “Positive”,
or N/A. An additional question related to romantic part-
n e r sw a sa sf o l l o w s :“Which of the following challenges
related to CF, if any, have you discussed with your partner
prior to making this commitment?” Participants
responded with a “yes” or “no” to items.
Statistical analyses
Data were analyzed using descriptive and inferential sta-
tistics. Unweighted demographic data are presented to
accurately reflect the population completing the survey.
All other data were weighted (using standard, iterative
sample balancing techniques) by region, age and gender
to match national adult CF norms, as provided by GfK
Roper from ongoing proprietary research it conducts
among patients with CF. This was done to facilitate
interpretation of the responses with regard to national
CF norms, without potentially confounding sample
biases (e.g. disproportionately high number of males ver-
sus females compared with national norms). Between-
group analyses for disease severity and gender were con-
ducted using Chi-square tests and only patients for
whom the question was appropriate were included in
analyses (e.g. only those who reported having co-work-
ers were included in the analysis regarding differences
in disclosure to coworkers). Disease severity was defined
as follows[1]: FEV1 % predicted 91-100 = Normal; 71-90
= Mild; 41-70 = Moderate; ≤ 40 = Severe. Effect sizes
were calculated from Cramer’s phi and then converted
to Cohen’s d to aid interpretation, with 0.20, 0.50, and
0.80 representing small, medium, and large effects,
respectively. Significance was defined as p < 0.05.
Results
Participant characteristics
In total, 865 completed surveys were included from
across the United States (US). This represented approxi-
mately 8% of the US adult CF population in the Cystic
Fibrosis Foundation Patient Registry[11]. Study partici-
pant characteristics are presented in Table 1.
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When evaluating the ‘all’ or ‘most of’ response options,
respondents were most likely to disclose to relatives
(94%) and close friends (81%; Figure 1). Fewer patients
reported disclosure to dating partners (73%), bosses/
supervisors/teachers (51%), co-workers (39%), neighbors
(25%) and acquaintances (20%).
Disclosure by lung function
Results indicated that while most adults reported that
they disclose their CF to relatives and close friends, dis-
closure to others was influenced by severity of lung dis-
ease (Figure 2). Patients with normal and mild disease
were less likely to have disclosed (e.g., ‘few’ or ‘none’
responses) to their co-workers (49 and 44%, respectively)
than those with moderate and severe disease (33 and
30%, respectively; c
2 (3, 561) = 11.87, p < .01; effect size
Cohen’sd=0 . 2 9 ). Similarly, patients with normal and
mild disease were less likely to have disclosed (e.g., ‘few’
or ‘none’ responses) to their bosses/supervisors/teachers
(45 and 37%, respectively) than those with moderate and
severe disease (27% and 27%, respectively; c
2 (3, 593) =
14.68, p < .01; effect size Cohen’sd=0 . 3 2 ). Conversely, a
significantly greater proportion of patients with severe
disease had disclosed to at least some acquaintances
(60%) compared with patients with moderate (45%), mild
(45%), and normal disease (40%) (c
2 (3, 714) = 12.70,
p < .01; effect size Cohen’s d = 0.27). No significant differ-
ences in disclosure by disease severity were found for
friends, relatives, dating partners or neighbors.
Perceived effects of disclosure on relationships
Patients reported that disclosure of their disease to
others generally had a neutral or positive effect on their
relationships (Figure 3). Relationships with relatives or
close friends were most likely to be positively affected
by disclosure (45 and 46%, respectively). Negative effects
of disclosure on relationships were reported infre-
quently; however, a negative effect was most likely to be
reported for dating partners or bosses/supervisors/tea-
chers (15% and 6%, respectively).
Gender differences in disclosure and challenges discussed
with partner following disclosure
There were no significant differences by gender in disclo-
sure to relatives, neighbors, acquaintances, bosses/
Table 1 Study participant characteristics
Variable Mean (SD)/Percentage
Age M = 29.9 ± 9.7 years; Median = 26.5 years; Range = 18-70 years
Age of diagnosis 5.8 (± 10.1) years; (76%; n = 658) diagnosed at ≤ 5 years of age
% Male 46%
% Race
Caucasian 95%
African American 2%
Hispanic 2%
Other 1%
% Education Level
a
Less than high school 5%
High school graduate 20%
Technical/Professional training 6%
Some college/college student 34%
College graduate 24%
Have/working on graduate degree 11%
% Marital Status
Single (not currently dating) 25%
Single (dating) 15%
Serious relationship 24%
Married 36%
% Disease Severity
b
Normal (> 90 FEV1 % predicted) 16%
Mild (70-90 FEV1 % predicted) 24%
Moderate (40 - 69 FEV1 % predicted) 29%
Severe (≤ 39 FEV1 % predicted) 15%
Note.
aPatients between 18-24 may not have the ability to have higher education level based on age. Education level thus represents the highest degree
achieved to date.
bDisease severity was unknown for 16% of the patients.
Modi et al. BMC Pulmonary Medicine 2010, 10:46
http://www.biomedcentral.com/1471-2466/10/46
Page 3 of 8supervisors/teachers, and coworkers. However females
were more likely to disclose (e.g. all/most of the time) to
both close friends (females 87% vs males 75%, c
2 (1, 858)
= 17.1, p < 0.0001; effect size Cohen’sd= 0.29) and dating
partners (females 52% vs males 43%, c
2 (1, 563) = 4.91,
p < 0.05; effect size Cohen’sd= 0.19). To better understand
disclosure while dating, patients with serious partners (e.g.
married, engaged or planning to live together; n = 548)
were asked to identify the most important issues they had
discussed prior to making a commitment. The most com-
monly discussed challenge was the daily, time-consuming
requirement for CF treatments (Table 2). Men were signif-
icantly more likely than women to discuss fertility issues
(86% versus 77%, respectively; c
2 (1, 549) = 6.78, p < .01;
effect size Cohen’sd=0 . 2 2 ), whereas women were more
likely to discuss healthcare cost/benefits (85% versus 75%,
respectively; c
2 (1, 549) = 8.63, p < .01; effect size Cohen’s
d=0 . 2 5 ), financial issues (83% versus 72%, respectively; c
2
(1, 549) = 9.34, p < .01; effect size Cohen’sd=0 . 2 6 )a n d
birth control methods (83% versus 65%, respectively; c
2 (1,
548) = 23.40, p<. 0 0 1 ;e f f e c ts i z eC o h e n ’sd=0 . 4 2 ). No
other significant gender differences were noted for other
common challenges, such as performing treatments, infec-
tion risk, or risk of CF in future children.
Discussion
While the challenges of disclosure of illness have been a
focus of research in HIV/AIDS, epilepsy and mental
health, minimal research has been conducted on disclo-
sure in CF [4-10]. Studies in other diseases have sug-
gested that two of the strongest influences on the
decision to disclose are concern about social stigma and
increasing health needs driven by disease severity [5,7,8].
Increasing survival of patients with CF and thus, greater
involvement of adults with CF in age-appropriate activ-
ities have made disclosure an increasingly important
topic in CF. The ADULT survey offered insight into the
activity and disclosure practices of a large, representative
sample of the US adult CF population.
Overall, results from the ADULT survey suggested
that most adults with CF are pursuing typical age-
appropriate activities, such as employment, independent
living, romantic relationships and marriage [2]. Two
particularly interesting aspects of this study were the
perceived effects of CF disclosure on relationships and
how these vary by type of relationship, disease severity,
and gender. The decision to disclose CF was shown to
be influenced by these factors, which are likely linked to
perceptions of the risks and benefits of disclosure
[3,4,12,13].
Specifically, patients were more likely to disclose their
condition to relatives and close friends than dating part-
ners, supervisors/employers/teachers or co-workers.
Among relatives and close friends, it is likely that some
level of personal intimacy has been established, making
it easier to disclose one’s medical condition. Relatives
Figure 1 Degree of disclosure by relationship group.
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Page 4 of 8Figure 2 Degree of disclosure by lung function. Pulmonary function categories reflect those defined by the CF Foundation[1]; severe = FEV1
≤40% predicted; moderate = FEV1 41-70% predicted; mild = FEV1 71-90% predicted; normal = FEV1 > 90% predicted; FEV1 = forced expiratory
volume in 1 second
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support for adults with CF in terms of disease manage-
ment, clinic visits and hospitalization[14]. Thus, it is
essential to disclose one’s condition to family members
and close friends, who may be needed in emergency
situations.
Disclosure to employers or potential romantic part-
ners appear, however, be more complicated. These
situations are directly related to the personal goals of
the adult with CF and, therefore, the perceived risk of a
negative reaction to disclosure is heightened. For exam-
ple, when pursuing a romantic relationship, patients
may be concerned about fertility issues[15], whereas in
the workplace, they may be concerned about their own
perceived limitations in relation to healthy colleagues
(e.g., needing time off for clinic visits or hospitaliza-
tions)[4]. In both situations, patients may choose to con-
ceal rather than disclose their condition because of the
potential risks of rejection. Although disclosure of CF is
not legally required for employment, there may be situa-
tions in which it is beneficial (e.g. letting employers
know why you are absent from work). Therefore, we
encourage CF teams to have a dialogue with their
patients about disclosure and the risk/benefit ratio of
disclosure in these contexts.
Severity of lung disease also influenced respondents’
approach to disclosure. More patients in the moderate
and severe disease groups disclosed to bosses/supervi-
sors/teachers, compared to patients with normal and
mild disease. These results are consistent with prior lit-
erature, suggesting that disclosure is more likely for
those with severe disease because the condition is more
difficult to conceal (e.g. more coughing or fatigue)[4].
Thus, Troster’s observation that disclosure is related to
perceived risk of detection is supported by data from
this large cohort of adults with CF[12]. Specifically,
patients with mild disease may consider their symptoms
less obvious and their bodily appearance/function more
‘normal’ in comparison to those with more severe
disease and, therefore, feel less need to risk disclosure of
their condition and its potential consequences.
Figure 3 Perceived effect of disclosure on relationships. Filtered for patients with identified relationships within each group for which CF
was disclosed
Table 2 Challenges related to cystic fibrosis discussed
with partners prior to making a serious commitment
Discussion topic Frequency of endorsement, %
Daily CF therapy 88
Possible time in hospital 86
Risk of CF in future children 82
Fertility issues 81
Healthcare costs/benefits 80
Financial issues 78
Infection risk 74
Birth control methods 74
Note. Filtered for patients who were either married, getting married in the
near future or planning to move in with a partner (n = 548).
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cifically, females were more likely to disclose to close
friends and dating partners than males. This is consis-
tent with studies showing that females with chronic
conditions are more likely to disclose their disease status
than males [5,9]. Women were also more likely to dis-
cuss issues related to healthcare, finances, and birth
control with their partners than men. One possible rea-
son is that disclosure in this context may elicit social
support from close friends and dating partners, which is
beneficial for their disease management.
Disclosure to neighbors and acquaintances was gener-
ally the lowest across types of relationships and disease
severity groups. However, disclosure to at least some
individuals within these groups was greater in those
with more severe disease. Patients with fewer symptoms
and a more ‘healthy’ appearance may feel that disclosure
in these situations is more bothersome than helpful[4].
Specifically, the public’s general knowledge of CF is rela-
tively low compared with other chronic illnesses and,
therefore, rather than explain CF in transient relation-
ships, it may be easier to relate milder symptoms to a
chest infection or a better recognized disease, such as
asthma. However, as symptoms and bodily appearance
worsens, becoming potentially more noticeable in casual
encounters, some patients preferred to disclose their
diagnosis rather than being perceived as having a stig-
matizing disease, such as HIV/AIDS.
Our finding that disclosure is associated with a per-
ceived neutral or positive effect on most relationships
supports a previous study indicating that lack of disclo-
sure can negatively impact peer evaluations[13]. Specifi-
cally, without an awareness of an individual’sd i a g n o s i s
of CF, peers may attribute symptoms or social absences
to other problems, which can lead to negative attribu-
tions and appraisals. For example, being shorter and
thinner than peers, or taking enzymes with food, may be
misunderstood by observers who are unaware of the
person’s condition. Thus ‘preventative disclosure’ [10],
as it is termed, may have a positive influence on rela-
tionships by increasing awareness and reducing misper-
ceptions. By definition, however, preventative disclosure
requires an analysis of the potential positive and nega-
tive effects of disclosure versus continued concealment.
Given that some perceived negative effects of disclosure
were reported for supervisors/employers/teachers or
romantic partners, it may be important for providers to
discuss disclosure in these social contexts.
Conclusions
The majority of adults with CF are now pursuing typi-
cal, age-appropriate adult activities that may require dis-
closure of their medical condition. The results of the
ADULT survey suggested that, although most adults
with CF choose to disclose their disease to relatives and
close friends, those with mild lung disease are less likely
to do so with supervisors/employers/teachers and
co-workers. On average, adultsr e p o r t e dt h a td i s c l o s u r e
was associated with a perceived positive or neutral
effect, with a few negative responses occurring with dat-
ing partners and employers. Healthcare providers may
want to counsel adult patients with CF on strategies for
disclosure of their condition in these more high-risk
situations.
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